Latest News

IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.

Rivian's R2 is now its best-selling vehicle, which could put the company one step closer to profitability.

Elon Musk may have scored another own goal.

Axon's revenue surged past $2.8 billion in 2025, but Figma's larger free cash flow tells a very different story about which growth model holds up.

Canopy's EU GMP certification spans its entire supply chain, so it can sell into Europe without relying on third parties.

Most investors haven't realized how much this company is exposed to artificial intelligence.

Acquisition lifted revenue, but a Fargo loss weighed on quarterly earnings.

Koppers (NYSE:KOP) lowered its 2026 earnings outlook after rising raw material and freight costs outpaced the company’s ability to recover them through pricing, even as third-quarter sales grew and year-to-date cash flow reached a record. The company reported third-quarter sales of $499 million, up

Kardigan (NASDAQ:KARD) said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study’s primary endpoint at 48 weeks, rather than 24 weeks. Top-line results are expected in the second half of 2027. The KATALYST-AV trial’s primary endp

Kennametal (NYSE:KMT) reported a sharp increase in earnings and sales for the first quarter of fiscal 2027, but the industrial tooling company said higher tungsten costs drove a substantial cash outflow and weighed on volumes in its Infrastructure business. Sales rose 54% both organically and on a

McKesson (NYSE:MCK) raised its fiscal 2027 adjusted earnings outlook after reporting higher second-quarter revenue and profit, supported by prescription volumes, specialty distribution and demand for medication access services. The company now expects adjusted earnings of $45.60 to $46.40 per dilut

Kinetik (NYSE:KNTK) expects full-year 2026 adjusted earnings before interest, taxes, depreciation and amortization to land at the high end of its guidance range after record processed gas volumes and stronger-than-expected third-quarter results. The midstream company reported third-quarter adjusted

Kayne Anderson BDC (NYSE:KBDC) reported higher third-quarter investment income and maintained its quarterly dividend, even as credit problems in several portfolio companies weighed on net asset value and pushed non-accruals higher. The business development company generated net investment income of

Kyndryl (NYSE:KD) reaffirmed its fiscal 2027 outlook after reporting higher margins and growth in its consulting business for the second quarter, even as total revenue declined from a year earlier. The technology infrastructure services company reported revenue of $3.65 billion for the quarter ende

Joby Aviation (NYSE:JOBY) raised its 2026 revenue guidance after a record third quarter for its Blade passenger business, while executives outlined plans to advance electric air taxi certification and pursue early commercial flights in 2027. The company reported third-quarter revenue of $55 million

Jackson Financial (NYSE:JXN) reported third-quarter 2026 adjusted operating earnings of $7.55 per diluted share, as growth in spread-based income and record annuity sales supported results. The company also reaffirmed its full-year capital generation and shareholder return targets. Chief Executive

Kadant (NYSE:KAI) reported record third-quarter revenue and adjusted earnings as aftermarket parts sales and acquisitions helped offset a slower market for large capital equipment projects. The company also raised its full-year adjusted earnings outlook. Revenue increased 15% from a year earlier to

The Nasdaq-100 pays about 0.6%. These five consumer stocks pay 5 times that, and one of them just closed the deal that makes it the owner of Tylenol.

Dutch Bros beat Q3 EPS and revenue estimates, but shares fell 21% as slowing customer traffic growth raised concerns about the sustainability of its aggressive store expansion plans.

Docusign holds a commanding revenue lead, but Monday.com's steeper growth rate is steadily narrowing the gap.

If you'd invested $5,000 in Berkshire stock 60 years ago, you would be sitting on a massive fortune today.

The e-commerce giant already carries its stake at around $239 billion. What changes when the Claude maker's stock trades?

RSPH offers broader sector diversification with lower volatility, while XBI delivers higher short-term gains but with steeper drawdowns.

Investors are pouring into dividend-paying stocks and ETFs as Democrats gain control of Congress.

Datadog's revenue is growing roughly three times faster than Docusign's, but the valuation gap between them is just as striking.